• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过免疫组织学检测到的骨髓浆细胞微聚集体可预测骨髓瘤患者在大剂量治疗后微小病变时的早期复发。

Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma.

作者信息

Wei Andrew, Westerman David, Feleppa Frank, Trivett Melanie, Juneja Surender

出版信息

Haematologica. 2005 Aug;90(8):1147-9.

PMID:16079123
Abstract

Plasma cell microaggregates detected by CD138 immunohistology were demonstrated in 22% of patients achieving morphologic remission 3 months after high-dose therapy for myeloma. Microaggregates were predictive of earlier disease progression, indicating that immunohistology may represent a useful tool in the assessment of minimal disease in patients after high-dose therapy for myeloma.

摘要

通过CD138免疫组织化学检测到的浆细胞微聚集体在接受骨髓瘤大剂量治疗3个月后达到形态学缓解的患者中占22%。微聚集体可预测疾病更早进展，这表明免疫组织化学可能是评估骨髓瘤大剂量治疗后患者微小疾病的有用工具。

相似文献

1
Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma.通过免疫组织学检测到的骨髓浆细胞微聚集体可预测骨髓瘤患者在大剂量治疗后微小病变时的早期复发。
Haematologica. 2005 Aug;90(8):1147-9.
2
Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.利用CD19、CD45、CD56、CD38和CD138对多发性骨髓瘤患者骨髓浆细胞进行流式细胞术评估及其与骨髓浸润率的相关性
Saudi Med J. 2004 Nov;25(11):1587-92.
3
Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.基于序列多态性的高灵敏度实时PCR检测异基因干细胞移植后浆细胞嵌合状态的动力学及其在多发性骨髓瘤患者微小残留病定量中的价值
Exp Hematol. 2006 May;34(5):688-94. doi: 10.1016/j.exphem.2006.01.011.
4
Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.用于检测骨髓浆细胞骨髓瘤中残留疾病的辅助研究比较。
Am J Clin Pathol. 2006 Jun;125(6):895-904. doi: 10.1309/B2P9-XEH4-4CY9-LPUK.
5
Using genomics to identify high-risk myeloma after autologous stem cell transplantation.
Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):77-80. doi: 10.1016/j.bbmt.2005.10.002.
6
The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells.骨髓活检标本的CD138免疫染色对量化MGUS和骨髓瘤中的骨髓受累情况的敏感性，包括浆细胞比例低的样本。
Haematologica. 2006 Jul;91(7):972-5.
7
Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients.骨髓活检联合免疫组织化学在骨髓瘤患者随访中优于骨髓穿刺。
J Clin Pathol. 2008 Feb;61(2):213-6. doi: 10.1136/jcp.2007.049130. Epub 2007 May 25.
8
Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.多发性骨髓瘤的流式细胞术免疫表型分析及微小残留病分析
Am J Clin Pathol. 2009 Nov;132(5):728-32. doi: 10.1309/AJCP1GYI7EHQYUYK.
9
Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.细胞遗传学与国际评分系统相结合可预测多发性骨髓瘤患者在大剂量化疗及自体干细胞移植后的不良预后。
Am J Hematol. 2009 May;84(5):283-6. doi: 10.1002/ajh.21390.
10
CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.在异基因干细胞移植后，CD4+CD25+FOXP3+调节性T细胞在多发性骨髓瘤患者的骨髓中重建并积聚。
Haematologica. 2008 Mar;93(3):423-30. doi: 10.3324/haematol.11897. Epub 2008 Feb 20.

引用本文的文献

1
Prognosis of multiple myeloma patients based on histopathological evaluation of bone marrow.基于骨髓组织病理学评估的多发性骨髓瘤患者的预后
Caspian J Intern Med. 2025 Jun 23;16(3):562-569. doi: 10.22088/cjim.16.3.562. eCollection 2025 Summer.
2
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma.根据新诊断多发性骨髓瘤的预后预测因子，RDW 的变化。
Sci Rep. 2024 Feb 3;14(1):2832. doi: 10.1038/s41598-024-53385-6.
3
Clinical Relevance of Interferon Regulatory Family-4 (IRF4) Expression in Newly Diagnosed Patients with Multiple Myeloma.
干扰素调节因子4（IRF4）表达在新诊断多发性骨髓瘤患者中的临床相关性
Indian J Hematol Blood Transfus. 2023 Oct;39(4):525-536. doi: 10.1007/s12288-023-01628-3. Epub 2023 Jan 16.
4
Microfluidic isolation of aptamers with affinity towards multiple myeloma monoclonal immunoglobulins.微流控技术分离对多发性骨髓瘤单克隆免疫球蛋白具有亲和力的适体。
Biomed Microdevices. 2022 Dec 8;25(1):3. doi: 10.1007/s10544-022-00643-x.
5
Rapid hybridization and immunohistochemistry: a pilot comparative study of two rapid diagnostic techniques for establishing monoclonality in plasma cell dyscrasias.快速杂交与免疫组织化学：两种用于浆细胞发育异常中单克隆性判定的快速诊断技术的初步比较研究
Med J Armed Forces India. 2020 Jan;76(1):103-108. doi: 10.1016/j.mjafi.2018.12.005. Epub 2019 Apr 5.
6
Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.受累/未受累重/轻链指数可预测移植后多发性骨髓瘤患者的病情进展。
Bone Marrow Transplant. 2017 Aug;52(8):1206-1207. doi: 10.1038/bmt.2017.97. Epub 2017 Jun 5.
7
What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.我们在谈论骨髓瘤微小残留病（MRD）时的含义。当前方法综述。两部分系列的第1部分。
Curr Hematol Malig Rep. 2014 Dec;9(4):379-88. doi: 10.1007/s11899-014-0238-x.
8
Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.骨髓穿刺和活检的联合评估对多发性骨髓瘤的预后具有优越性。
Diagn Pathol. 2010 May 18;5:30. doi: 10.1186/1746-1596-5-30.
9
Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.多发性骨髓瘤中骨髓浆细胞浸润的评估：CD138免疫组织化学的附加价值
Hum Pathol. 2007 Dec;38(12):1779-87. doi: 10.1016/j.humpath.2007.04.010. Epub 2007 Aug 21.